Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD)

European Journal of Internal Medicine

Volumn 21, Issue 3, 2010, Pages 208-215

  Zimmermann, Tim ^a   Hoppe Lotichius, Maria ^a   Tripkovic, Vuk ^a   Barreiros, Ana P ^a   Wehler, Thomas C ^a   Zimmermann, Anca ^a   Schattenberg, Jörn M ^a   Heise, Michael ^a   Biesterfeld, Stefan ^a   Galle, Peter R ^a   Otto, Gerd ^a   Schuchmann, Marcus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Autoimmune liver disease; Immunological disorder; Liver transplantation; Preoperative immunosuppression; PTLD

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BONE MARROW BIOPSY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; SURGICAL RISK;

ADOLESCENT; ADULT; AGED; CADAVER; CHILD; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STEROIDS; TISSUE DONORS; YOUNG ADULT;

EID: 77952292247     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.02.009     Document Type: Article

References (30)

1. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 2 (2004) 222-230
2. Menachem Y., Safadi R., Ashur Y., and Ilan Y. Malignancy after liver transplantation in patients with premalignant conditions. J Clin Gastroenterol 36 5 (2003) 436-439
3. Zein N.N., Perez R.G., and Wiesner R.H. Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation. Hepatology 31 3 (2000) 808-809
4. Duvoux C., Pageaux G.P., Vanlemmens C., et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74 8 (2002) 1103-1109
5. Lemoine A., Pham P., Azoulay D., et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 98 5 (2001) 1332-1338
6. Jain A., Nalesnik M., Reyes J., et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236 4 (2002) 429-436 discussion 436-7
7. Aucejo F., Rofaiel G., and Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?. J Hepatol 44 1 (2006) 19-23
8. Dotti G., Fiocchi R., Motta T., et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74 8 (2002) 1095-1102
9. Ghobrial I.M., Habermann T.M., Macon W.R., et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation 79 2 (2005) 244-247
10. Leblond V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 16 6 (1998) 2052-2059
11. Hoover R., and Fraumeni Jr. J.F. Risk of cancer in renal-transplant recipients. Lancet 2 7820 (1973) 55-57
12. Kinlen L.J., Sheil A.G., Peto J., and Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2 6203 (1979) 1461-1466
13. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 4 (2000) 514-519
14. Grulich A.E., Vajdic C.M., and Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 16 3 (2007) 405-408
15. Eriksson N.E., Mikoczy Z., and Hagmar L. Cancer incidence in 13811 patients skin tested for allergy. J Investig Allergol Clin Immunol 15 3 (2005) 161-166
16. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 3 (2006) 692-701
17. Becker T., Foltys D., Bilbao I., et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 86 12 (2008) 1689-1694
18. Harris N.L., Ferry J.A., and Swerdlow S.H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14 1 (1997) 8-14
19. Gabriel C.M., Gregson N.A., Wood N.W., and Hughes R.A. Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a). J Neurol Neurosurg Psychiatry 72 2 (2002) 230-235
20. Koch D.G., Christiansen L., Lazarchick J., Stuart R., Willner I.R., and Reuben A. Posttransplantation lymphoproliferative disorder - the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 13 6 (2007) 904-912
21. Guthery S.L., Heubi J.E., Bucuvalas J.C., et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 75 7 (2003) 987-993
22. Caillard S., Lelong C., Pessione F., and Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 6 11 (2006) 2735-2742
23. Funch D.P., Ko H.H., Travasso J., et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 80 9 (2005) 1174-1180
24. Kremers W.K., Devarbhavi H.C., Wiesner R.H., Krom R.A., Macon W.R., and Habermann T.M. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6 5 Pt 1 (2006) 1017-1024
25. Shpilberg O., Wilson J., Whiteside T.L., and Herberman R.B. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 36 1-2 (1999) 109-121
26. Cholongitas E., Pipili C., Kaklamanis L., and Dasenaki M. Is there any association between non-Hodgkin's lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome?. Dig Dis Sci 53 3 (2008) 867-868
27. Varoczy L., Gergely L., Zeher M., Szegedi G., and Illes A. Malignant lymphoma-associated autoimmune diseases - a descriptive epidemiological study. Rheumatol Int 22 6 (2002) 233-237
28. Werner M., Almer S., Prytz H., et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 50 2 (2009) 388-393
29. Smedby K.E., Hjalgrim H., Askling J., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98 1 (2006) 51-60
30. Teufel A., Weinmann A., Centner C., et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 15 5 (2009) 578-582